US 11419934
Use of VDAS to enhance immunomodulating therapies against tumors
granted A61KA61K2039/505A61K31/661
Quick answer
US patent 11419934 (Use of VDAS to enhance immunomodulating therapies against tumors) held by Oncotelic Therapeutics, Inc. expires Mon Aug 18 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Oncotelic Therapeutics, Inc.
- Grant date
- Tue Aug 23 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 18 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 5
- CPC classes
- A61K, A61K2039/505, A61K31/661, A61K31/6615, A61K39/395